NEW YORK — Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.
Under the terms of the deal, Novogene will develop a companion diagnostic for chiauranib, a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation. Novogene will also provide molecular testing services to Chipscreen during clinical testing of the drug.